Express Pharma

Unichem Laboratories posts FY 15 consolidated and standalone results

Standalone revenue from operations stood at Rs 255.9 crores

Unichem Laboratories has posted its FY 15 consolidated and standalone results. The company’s standalone revenue from operations stood at Rs 255.9 crores for the quarter ended March 31, 2015 as against Rs 244.1 crores recorded during the corresponding quarter of the previous year. Revenues from domestic formulations stood at Rs 146.2 crores as against Rs 139.1 crores in the same period last year.

Revenues from international formulations business came in at Rs 82.8 crores as compared to Rs 74.4 crores in the corresponding quarter of previous year. Revenues from API business (excluding captive consumption for formulation business) came in at Rs 21.5 crores for the quarter ended March 31, 2015 as compared to Rs 24 crores recorded during the same quarter of the previous year.

The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) for the quarter stood at Rs 14.8 crores.

The net profit for the quarter came in at Rs 9.8 crores as against Rs 30.5 crores which includes exceptional gains from same quarter of previous year. The EPS-diluted for the current quarter stood at Rs 1.08.

The company’s standalone revenue from operations stood at Rs 1,090.9 crores for the year ended March 31, 2015 as against Rs 1,044.2 crores recorded in the same period last year. Revenues from domestic formulations stood at Rs 650.9 crores as against Rs 655 crores in the same period last year. Revenues from international formulations business came in at Rs 312.8 crores as compared to Rs 255.2 crores in the corresponding period of previous year. Revenues from API business (Excluding captive consumption for formulation business) came in at Rs 113.1 crores for the year ended March 31, 2015 as compared to Rs. 118.7 crores recorded in the same period of previous year.

The company’s EBITDA for the year stood at Rs. 101.6 crores. The net profit for the year ended March 31, 2015 came in at Rs 64.4 crores as against Rs 176.9 crores which includes exceptional gains from the same period of previous year. The EPS-diluted for the year ended March 31, 2015 stood at Rs 7.08.

The board has recommended dividend of 100 per cent i.e, Rs 2 per equity share of face value of Rs 2 each.

EP News BureauMumbai

Comments are closed.